Literature DB >> 23122817

1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, a novel compound class with potent chemoreversal activity.

Hsin-Yi Hung1, Emika Ohkoshi, Masuo Goto, Kyoko Nakagawa-Goto, Kuo-Hsiung Lee.   

Abstract

1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, which share a fragment from (±)-3'-O-4'-O-bis(3,4-dimethoxycinnamoyl)-cis-khellactone (DMDCK) and 3'R,4'R-disubstituted-2',2'-dimethyldihydropyrano[2,3-f]chromone (DSP), exhibited remarkable chemoreversal activity on multidrug resistant human nasopharyngeal carcinoma (KB) when combined with three anticancer drugs, paclitaxel, vincristine and doxorubicin. Among 15 novel synthesized analogs, bis-trimethoxybenzoyl derivative 15 was the most active (340-fold more active than verapamil when used with vincristine) followed by two di-cinnamoyl derivatives, 10 and 11, and then di-cyclohexanecarbonyl derivative 9. All aliphatic chain derivatives, 3-5, showed no activity. Structure-activity relationship study indicated that a di-ester structure was critical to enhance the activity resulting from the maintenance of the spatial arrangement proposed by the pharmacophore based on the verapamil-binding site. Further mechanism of action study showed 15 inhibited mainly P-glycoprotein efflux pump function, while 13 exhibited an additional multidrug resistance-associated protein efflux pump function.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122817      PMCID: PMC3508342          DOI: 10.1016/j.bmcl.2012.09.096

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.

Authors:  Hsin-Yi Hung; Emika Ohkoshi; Masuo Goto; Kenneth F Bastow; Kyoko Nakagawa-Goto; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-05-21       Impact factor: 7.446

3.  Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  J Med Chem       Date:  2002-12-19       Impact factor: 7.446

Review 4.  Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?

Authors:  Valentina Fodale; Mariaelena Pierobon; Lance Liotta; Emanuel Petricoin
Journal:  Cancer J       Date:  2011 Mar-Apr       Impact factor: 3.360

5.  Antitumor agents 286. Design, synthesis, and structure-activity relationships of 3'R,4'R-disubstituted-2',2'-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance.

Authors:  Ting Zhou; Qian Shi; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2010-11-17       Impact factor: 7.446

6.  Chemotherapeutic resistance: surviving stressful situations.

Authors:  Luke A Gilbert; Michael T Hemann
Journal:  Cancer Res       Date:  2011-07-19       Impact factor: 12.701

7.  Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors.

Authors:  Ilza K Pajeva; Christoph Globisch; Michael Wiese
Journal:  ChemMedChem       Date:  2009-11       Impact factor: 3.466

8.  Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.

Authors:  Wang-Fun Fong; Xiao-Ling Shen; Christoph Globisch; Michael Wiese; Guang-Ying Chen; Guo-Yuan Zhu; Zhi-Ling Yu; Anfernee Kai-Wing Tse; Ying-Jie Hu
Journal:  Bioorg Med Chem       Date:  2008-02-13       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.